Table 2 Study Design and Patient Baseline Characteristics
| Â | Baseline Characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Study | n | Duration | Treatments | Age | Male | Weighta | Bipolar I | MADRS | CG-BP-S-Overall | CGI-BP-S- Depression |
Calabrese et al. | 511 | 8 weeks | Quetiapine IR 300 mg Quetiapine IR 600 mg Placebo | 37.4 | 41.9% | NR | 66.9% | 30.4 | 4.4 | NR |
Durgam et al. | 571 | 8 weeks | Cariprazine 0.75 mg Cariprazine 1.5 mg Cariprazine 3.0 mg Placebo | 41.9 | 37.7% | 80.9 | 100.0% | 30.6 | 4.4 | NR |
Earley et al. Study 1) | 480 | 6 weeks | Cariprazine 1.5 mg Cariprazine 3.0 mg Placebo | 42.8 | 40.8% | 86.5 | 100.0% | 30.6 | 4.5 | NR |
Earley et al. Study 2) | 490 | 6 weeks | Cariprazine 1.5 mg Cariprazine 3.0 mg Placebo | 43.6 | 37.3% | 84.78 | 100.0% | 31.4 | 4.5 | NR |
Li et al. | 279 | 8 weeks | Quetiapine XR 300 mg Placebo | 33.1 | 48.1% | 64.5 | 50.9% | 28.7 | NR | 4.5 |
Loebel et al.b | 485 | 6 weeks | Lurasidone 20–60 mg Lurasidone 80–120 mg Placebo | 41.5 | 41.4% | 77.2 | 100.0% | 30.5 | 4.5 | 4.5 |
Lombardo et al. Study 1) | 504 | 6 weeks | Ziprasidone 40–80 mg Ziprasidone 120–160 mg Placebo | 39.9 | 43.6% | NR | 100.0% | 28.2 | NR | NR |
Lombardo et al. Study 2) | 381 | 6 weeks | Ziprasidone 20–80 mg Placebo | 40.2 | 42.5% | NR | 100.0% | 28.4 | NR | NR |
McElroy et al. | 582 | 8 weeks | Quetiapine IR 300 mg Quetiapine IR 600 mg Placebo | 38.5 | 36.9% | 80.8 | 64.0% | 26.9 | 4.2 | NR |
Suppes et al. | 270 | 8 weeks | Quetiapine XR 300 mg Placebo | 39.5 | 35.5% | 88.8 | 80.4% | 30.0 | 4.5 | NR |
Thase et al. | 467 | 8 weeks | Quetiapine IR 300 mg Quetiapine IR 600 mg Placebo | 37.7 | 43.1% | NR | 67.4% | 30.2 | 4.5 | NR |
Thase et al. (Study 1) | 374 | 8 weeks | Aripiprazole 5–30 mg Placebo | 39.0 | 37.5% | 87.2 | 100.0% | 28.8 | NR | 4.3 |
Thase et al. (Study 2) | 375 | 8 weeks | Aripiprazole 5–30 mg Placebo | 40.5 | 40.0% | 86.8 | 100.0% | 29.0 | NR | 4.4 |
Tohen et al. | 747 | 8 weeks | Olanzapine > 5 mgc Placebo | 42.0 | 41.5% | NR | 100.0% | 32.0 | NR | 4.9 |
Tohen et al. | 514 | 6 weeks | Olanzapine 10–20 mg Placebo | 35.5 | 44.3% | NR | 100.0% | 29.0 | NR | 4.5 |
Wang et al. | 68 | 8 weeks | Olanzapine 10–20 mg Placebo | 29.2 | 41.2% | 63.9 | 100.0% | 28.6 | 4.4 | NR |
Young et al. | 647 | 8 weeks | Quetiapine IR 300 mg Quetiapine IR 600 mg Placebo | 42.2 | 41.6% | 75.5 | 61.6% | 28.3 | 4.3 | NR |
Yatham et al. | 224 | 8 weeks | Cariprazine 0.25–0.75 mg Cariprazine 1.5–3.0 mg Placebo | 38.9 | 34.3% | NR | 72.7% | 30.4 | 4.4 | NR |